WO1999027842A1 - Test du champ visuel par telemedecine - Google Patents
Test du champ visuel par telemedecine Download PDFInfo
- Publication number
- WO1999027842A1 WO1999027842A1 PCT/US1998/025485 US9825485W WO9927842A1 WO 1999027842 A1 WO1999027842 A1 WO 1999027842A1 US 9825485 W US9825485 W US 9825485W WO 9927842 A1 WO9927842 A1 WO 9927842A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- local
- responses
- remote
- patient
- visual field
- Prior art date
Links
- 230000000007 visual effect Effects 0.000 title claims abstract description 85
- 238000012360 testing method Methods 0.000 title claims abstract description 81
- 238000000034 method Methods 0.000 claims abstract description 21
- 230000004044 response Effects 0.000 claims description 32
- 230000005540 biological transmission Effects 0.000 claims description 12
- 238000013528 artificial neural network Methods 0.000 claims description 9
- 238000012544 monitoring process Methods 0.000 claims description 6
- 230000002123 temporal effect Effects 0.000 claims description 5
- 230000004913 activation Effects 0.000 claims 2
- 230000003213 activating effect Effects 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 abstract description 28
- 238000012216 screening Methods 0.000 abstract description 8
- 230000002452 interceptive effect Effects 0.000 abstract description 6
- 238000012545 processing Methods 0.000 abstract description 4
- 208000012902 Nervous system disease Diseases 0.000 abstract description 3
- 208000025966 Neurological disease Diseases 0.000 abstract description 3
- 230000004382 visual function Effects 0.000 abstract description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 238000003745 diagnosis Methods 0.000 description 10
- 201000010099 disease Diseases 0.000 description 10
- 201000004569 Blindness Diseases 0.000 description 8
- 230000002159 abnormal effect Effects 0.000 description 6
- 210000001328 optic nerve Anatomy 0.000 description 6
- 208000006011 Stroke Diseases 0.000 description 5
- 230000035945 sensitivity Effects 0.000 description 4
- 230000002596 correlated effect Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000013507 mapping Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000000926 neurological effect Effects 0.000 description 3
- 208000002177 Cataract Diseases 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000004410 intraocular pressure Effects 0.000 description 2
- 210000003126 m-cell Anatomy 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 238000003909 pattern recognition Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 210000001525 retina Anatomy 0.000 description 2
- 238000012549 training Methods 0.000 description 2
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 208000016192 Demyelinating disease Diseases 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 208000003098 Ganglion Cysts Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010039729 Scotoma Diseases 0.000 description 1
- 208000005400 Synovial Cyst Diseases 0.000 description 1
- 208000013449 Visual field disease Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 238000005094 computer simulation Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 210000000320 geniculate body Anatomy 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 230000008450 motivation Effects 0.000 description 1
- 208000001491 myopia Diseases 0.000 description 1
- 210000004126 nerve fiber Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 210000003977 optic chiasm Anatomy 0.000 description 1
- 208000020911 optic nerve disease Diseases 0.000 description 1
- 239000013307 optical fiber Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000007781 pre-processing Methods 0.000 description 1
- 238000000513 principal component analysis Methods 0.000 description 1
- 210000001747 pupil Anatomy 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000013139 quantization Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 238000010206 sensitivity analysis Methods 0.000 description 1
- 238000005549 size reduction Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000004304 visual acuity Effects 0.000 description 1
- 230000003945 visual behavior Effects 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/68—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient
- A61B5/6801—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient specially adapted to be attached to or worn on the body surface
- A61B5/6813—Specially adapted to be attached to a specific body part
- A61B5/6814—Head
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B3/00—Apparatus for testing the eyes; Instruments for examining the eyes
- A61B3/02—Subjective types, i.e. testing apparatus requiring the active assistance of the patient
- A61B3/028—Subjective types, i.e. testing apparatus requiring the active assistance of the patient for testing visual acuity; for determination of refraction, e.g. phoropters
- A61B3/032—Devices for presenting test symbols or characters, e.g. test chart projectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/72—Signal processing specially adapted for physiological signals or for diagnostic purposes
- A61B5/7235—Details of waveform analysis
- A61B5/7264—Classification of physiological signals or data, e.g. using neural networks, statistical classifiers, expert systems or fuzzy systems
- A61B5/7267—Classification of physiological signals or data, e.g. using neural networks, statistical classifiers, expert systems or fuzzy systems involving training the classification device
Definitions
- This invention is in the field of visual field screening.
- glaucoma is one of the leading causes of blindness. Unlike cataract blindness, which is correctable with modern surgical techniques, blindness from glaucoma is permanent.
- the target organ of glaucoma is the optic nerve, which transmits signals of light from the retina to the brain. No known method is available for repairing, or transplanting, an injured optic nerve. Millions upon millions of patients throughout the world have glaucoma and are completely unaware of this.
- the particularly sad aspect of glaucoma blindness is that it is generally preventable with proper diagnosis and treatment.
- Glaucoma which causes absolute, total blindness when untreated, is no exception.
- a second major diagnostic problem is that visual loss from glaucoma is, almost without exception, painless.
- the patient is unaware of the ravages of glaucoma until it is too late.
- a "tonometer" to measure the intraocular pressure
- the diagnosis can be made whenever the pressure within the eye is significantly elevated.
- tonometry is not available in many parts of the world; and many patients have the "low-tension" form of glaucoma in which the intraocular pressure is completely normal. Therefore, reliance upon tonometry, in areas of the world where this is available, frequently leads to a blatantly false sense of security.
- the patient is told that glaucoma is not present, when, in reality, the disease is insidiously attacking the patient's optic nerve, causing irreversible neurological damage to the visual system.
- the present invention provides an extremely inexpensive vehicle for addressing the serious problem of glaucoma blindness throughout the world.
- Screening software programs can be accessed by the patient's personal computer (or by any computer available to the patient, such as that of a friend or of a local clinic) from the Internet or other telemetric vehicle.
- a computer monitor, a television screen, or some other local video display system may be used, with the software programs being operated entirely on a remote computer to generate the desired stimuli on the local video display system. Therefore, the entire testing process can be performed via long-distance transmission vehicles, such as, but not limited to, the Internet, or an optical fiber network, thus providing, telemetrically, not only essentially instantaneous auto interpretation, but also telemetric monitoring of the patient's performance of the test in real time.
- At least gross telemetric monitoring is available by monitoring the speed of the patient's responses, as well as the response itself and whether it makes rational sense, based upon nomograms of typical patient visual behavior.
- Computers or systems available to the patient with audio capability such as an audio card, can provide audio feedback stimuli, such as voice, or a tone or series of tones, to monitor the test performance in real-time and provide interactive feedback to the patient.
- a patient can receive a "grade" correlated with demonstrated responsiveness and concentration ability, thus indicating whether the patient's performance is satisfactory for meaningful autointerpretation.
- a central world-wide monitoring and data collection station can link the system and provide multiweb-like integration.
- the Internet provides virtually instantaneous, extremely affordable, world-wide access.
- the present telemedicine system is "intelligent," in that ongoing data accumulation and analyses thereof improve the computational model and provide, over time, increasingly more accurate identification of more subtle disease processes.
- Figure 1 is a schematic diagram of the information flow in the system of the present invention.
- Figure 2 is a schematic diagram of the automatic interpretation portion of the system of the present invention.
- the present invention provides a quick and easy world-wide visual field screening system via the Internet, or via some other long-distance telemedicine vehicle. All that is required is for the patient to access the software programs which in real-time interactively present, monitor, and instantaneously autointerpret the visual field screening test.
- the software programs can be accessed via telemedicine, such as "going on-line" on the Internet.
- the proposed invention utilizes "frequency doubling” and “noise-field campimetry” software programs for quick and efficient visual screening of the patient on his or her own display system. These two types of programs are well known in the art.
- An alternative embodiment of the proposed invention includes flicker and temporal modulation perimetry, as described in work published by Lachenmayr, and work published by Casson.
- High temporal flicker frequencies stimulate, on a preferential basis, ganglion cells projecting to the magnocellular layers of the lateral geniculate body. These axons are called M-cell fibers, and it is these nerve fibers which are postulated to be preferentially damaged in glaucoma. Detection of damage to M-cell fibers, then, helps make the diagnosis of glaucoma in its earlier stages.
- Flicker perimetry is an excellent tool with patients who also have cataract formation.
- the Lachenmayr method uses the highest frequency of flicker, called the "critical flicker frequency", which is detected for a 100 per cent contrast flicker target.
- the Casson method employs a group of frequencies, such as temporal frequencies of 2, 8, and 16 Hz.
- Another alternative embodiment of the proposed invention employs color-on- color visual field strategies. This embodiment requires that the patient have access to a color video monitor or color television.
- One such strategy currently known in the art, is called "short wavelength automated perimetry". The advantage of this strategy is that defects are believed to become apparent several years before being noted on standard automated perimetry visual field tests.
- Still another alternative embodiment of the proposed invention employs motion, or "kinetic" perimetry strategies, which are currently well known in the art.
- the system of the present invention includes a local visual field test apparatus 5, which can include a display screen, such as a television or a computer monitor.
- the local apparatus may also include a local computer. It is recognized that using the patient's display system may not provide quite the degree of accuracy of the best available perimeter systems. Extremely subtle visual field changes are more difficult to notate on a computer or television display. Deficiencies include the fact that ambient lighting conditions will vary from one person's home to another. The "texture" and luminosity of one person's display screen will vary from that of another person. Some display screens have adjustable "brightness,” and some do not.
- “Gamma calibration” a procedure well known in the art, is one strategy which can be used in the software incorporated in the present invention, as a standardization aid.
- Visual field testing utilizing a video display as the visual fixation source may not equal the accuracy attainable with a full threshold first-class globe perimeter; nevertheless, the present invention can achieve an initial accuracy level of 75 to 80 per cent, and maybe more.
- Providing this degree of test accuracy via a world- wide telemetric system, such as the Internet, for interactive real-time performance and for instantaneous autointerpretation of visual screening test results, will play a major role in eliminating world-wide glaucoma blindness.
- a screening "preliminary" diagnosis can be then be confirmed, and, if glaucoma is present, proper glaucoma treatment can be instituted.
- the proposed invention may well spare millions and millions of patients throughout the world blindness and the ravages of undiagnosed glaucoma.
- visual field testing with the present invention can also be used to test for a variety of neurological disorders, including cerebrovascular accidents ("strokes"), trauma, brain tumors, and other diseases.
- strokes cerebrovascular accidents
- trauma trauma, brain tumors, and other diseases.
- brain tumors Generally speaking, strokes and major neurological brain diseases cause quite large visual field deficits, and the proposed invention will readily help make the diagnosis of these disorders.
- Some of the inventors of the present invention have also developed a method and an apparatus for automatic, computerized interpretation of the visual function test parameters obtained in a head-mounted display virtual realty testing system.
- the data produced by the testing system are automatically reviewed and correlated with previously-determined patterns recognized to be "normal” or "abnormal,” and clinical diagnoses for pathological conditions are thereby suggested to the clinician.
- Telemedicine can be utilized to receive test data from the patient and to transmit the test inte ⁇ retation, including the suspected diagnosis, or diagnoses, and recommendations for further clinical correlation or for further ancillary tests.
- Telemedicine can be employed to monitor interactively and automatically, in real time, the patient's performance of the visual field test.
- the system of the present invention similarly uses clustering algorithms, linear and non-linear mapping algorithms, and pattern recognition algorithms, either individually or as a combination thereof.
- the remote computing system consists of a central processing system and data repository 18, as shown in Figure 1.
- a database of empirical, semi-empirical, or simulated visual field test data is used to build a model of the visual field test data.
- This model when applied to previously unseen test results, is capable of automatically interpreting and classifying the test data in terms of the presence and/or severity of abnormal (diseased) regions and states.
- the data processing portion of the system provides not only the classification of the visual field test data in terms of presence or absence of all disease, or any particular disease (e.g., glaucoma), but also may assign a probability of detection and/or a numerical value indicating the severity of the disease. This provides a tool for monitoring disease progression.
- the automatic inte ⁇ retation portion of the system may be a binary classification system, which will indicate the presence or absence of a particular disease, such as glaucoma, or a multi-class system, which provides recognition and classification of a large variety of possible visual field disorders, including, but not limited to, neurological tumors, cerebrovascular accidents and strokes, optic nerve disorders, compression syndromes of the optic nerve or optic chiasm, demyelinating diseases, and diseases of the retina.
- a binary classification system which will indicate the presence or absence of a particular disease, such as glaucoma
- a multi-class system which provides recognition and classification of a large variety of possible visual field disorders, including, but not limited to, neurological tumors, cerebrovascular accidents and strokes, optic nerve disorders, compression syndromes of the optic nerve or optic chiasm, demyelinating diseases, and diseases of the retina.
- the system of the present invention utilizes the results of visual stimuli consisting of dots, symbols, shapes, or patterns, etc., with or without color, depending upon the capability of the patient's display screen. These are presented to the patient in the form, preferentially, of such visual screening programs as frequency doubling and noise-field campimetry, but also including standard automated perimetry visual testing schemes such as those used by the Humphrey Field Analyzer.
- Noise-field campimetry can be used to present visual stimuli to the patient utilizing the entire display screen, called “full-field” noise-field campimetry.
- a completely new technique called “focal” or “segmental” noise-field campimetry can also be employed as a visual testing strategy in the proposed invention.
- focal area of the display screen is utilized to test visual function responses of the patient.
- these visual stimuli are converted into numerical representation for data processing.
- Other inputs resulting from standard pre-processing of the test data, such as visual field indices, can also be employed by the inte ⁇ retation system. Inclusion of all available individual components of perimetric examination is useful for proper clinical inte ⁇ retation of the visual test examination.
- the information provided to the automated inte ⁇ retation system may include: ancillary data, such as pupil size during testing (as estimated or measured by an independent observer of the patient), the patient's age, and visual acuity (which can be measured for near vision by the testing program); reliability indices, such as fixation behavior and accuracy, and response fluctuation; visual field indices, such as average deviation of sensitivity at each test location from age-adjusted normal population values, the index of the degree of irregularity of visual field sensitivity about the normal slope, and sensitivity analysis of clusters of points; results of point-by-point comparison of test results with age- matched normal population values; results of high-pass resolution perimetry (with resolution limitations ascribed, among other considerations, to the innate quality and performance capabilities of the patient's computer system and display monitor); results of flicker and temporal modulation perimetry; results of color-on-color perimetry testing strategies, using a color video monitor or television; results of motion, or "kinetic", perimetry visual field testing strategies
- the implementation may be in the form of a single-level system or a hierarchical system.
- the single-level system all the input data which are deemed relevant for the inte ⁇ retation task, are inputted and processed simultaneously.
- the hierarchical system different input data types are modeled by dedicated separate sub-systems, and these outputs are subsequently fused through a suitable computational architecture, such as a neural network, to produce the final classification result.
- the automatic inte ⁇ retation system can consist of the following modules: clustering/data reduction module 22, which may employ singular value decomposition, principal component analysis, learning vector quantization, or other clustering or data size reduction methods; data normalization module 24; data classification module 26, which performs pattern recognition, classification, and quantification of the visual field test data through nonlinear or linear mapping.
- This function may be accomplished through the use of multilayer perceptron neural network and other neural network architectures, or through non-linear, multivariate, or linear regression of the data, or by multivariate statistical classifiers or discriminators (such as Bayesian classifiers); output module 28, creating a graphical representation of the visual field test data, such as isopter/scotoma plots, or gray scale or color-coded plots, with superimposed identification of the regions that the system classified as abnormal.
- the automatic inte ⁇ retation system is an expert system automatically trained on a set of empirical, semi-empirical, and/or simulated data.
- the construction of a proper training database is essential for achieving good performance of the inte ⁇ retation system, including good sensitivity and specificity.
- the training database may contain all, or any, of the following types of visual field data: empirical data, i.e., data obtained for patients with normal and abnormal visual fields; semi-empirical data, i.e., data obtained by modification of the empirical data, as described above, by: emphasizing or de-emphasizing certain aspects of the visual field test to bring out the characteristic features of certain diseased states; adding noise or measurement uncertainty component(s) which may be associated with a real visual field examination; any other modification of the visual field test data and their associated classification; and, simulated data, i.e., data that are constructed to simulate the real- world results of a visual field test for both normal and abnormal visual fields.
- empirical data i.e., data obtained for patients with normal and abnormal visual fields
- semi-empirical data i.e., data obtained by modification of the empirical data, as described above, by: emphasizing or de-emphasizing certain aspects of the visual field test to bring out the characteristic features of certain diseased states; adding noise or measurement
- Telemedicine is utilized to receive test data from the patient and to transmit the test inte ⁇ retation, including the suspected diagnosis, or diagnoses, and recommendations for further clinical correlation or for further ancillary tests. Telemedicine is also employed to monitor interactively and automatically, in real time, the patient's performance of the visual field test.
- the content of the software is dictated by the need to provide technically acceptable protocols, such as for examining the field of view and deficiencies thereof, utilizing measurements of thresholds for pattern discrimination, sensitivity to light intensity, or, if desired and available on the patient's display monitor, color.
- the preferred embodiment includes frequency doubling and noise-field campimetry (both "full field” campimetry, and "focal” noise-field campimetry), as these are very amenable to testing on a display monitor screen.
- Active feedback sensing can alert the system to patient loss of attention, for notation and reiteration of test stimuli. Individual test points are reiterated when a result is found to be inconsistent with a predetermined norm.
- Audio feedback stimuli can present a voice, or a tone or series of tones, to monitor the test performance in real-time and to provide interactive feedback. Each eye is tested individually by occluding the non-tested eye.
- Specific instructions are given to the patient to establish the proper geometric conditions for test performance, such as the recommended distance from the eyes to the patient's display screen, and head placement relationhip thereto. It is important that the dimensions of the patient's display screen be known. These dimensions, as well as the display screen's manufacturer and model number, can be readily transmitted to the central station computer, so that the software can provide necessary viewing distance instructions and other pertinent recommendatons. Widening the field of view is easily accomplished by simply decreasing the distance from the patient's eyes to the display monitor.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medical Informatics (AREA)
- Biophysics (AREA)
- Surgery (AREA)
- Animal Behavior & Ethology (AREA)
- Physics & Mathematics (AREA)
- Public Health (AREA)
- Ophthalmology & Optometry (AREA)
- Pathology (AREA)
- Eye Examination Apparatus (AREA)
- Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
Abstract
Cette invention se rapporte à un procédé et à un appareil servant à la réalisation et à l'auto-interprétation, via l'Internet ou via un autre moyen de télémétrie, des paramètres d'un test de la vue, obtenus lors d'une détection interactive du champ visuel à l'aide d'un écran d'affichage local. Ce test interactif et l'auto-interprétation instantanée des performances du champ visuel à l'aide d'un écran d'affichage local (5) et d'un dépôt central de données/traitement de données (18) par télémédecine permettent de dépister les glaucomes et d'autres troubles neurologiques affectant l'organe de la vue. La télémédecine, par exemple via l'Internet, permet d'utiliser un tel système à l'échelle planétaire, y compris dans des régions où des médecins ne sont pas présents.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002312924A CA2312924A1 (fr) | 1997-12-04 | 1998-12-02 | Test du champ visuel par telemedecine |
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US6752197P | 1997-12-04 | 1997-12-04 | |
US60/067,521 | 1997-12-04 | ||
US8981798P | 1998-06-19 | 1998-06-19 | |
US60/089,817 | 1998-06-19 | ||
US9021498P | 1998-06-22 | 1998-06-22 | |
US60/090,214 | 1998-06-22 | ||
US09/179,112 US6027217A (en) | 1996-07-31 | 1998-10-26 | Automated visual function testing via telemedicine |
US09/179,112 | 1998-10-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1999027842A1 true WO1999027842A1 (fr) | 1999-06-10 |
Family
ID=27490636
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1998/025485 WO1999027842A1 (fr) | 1997-12-04 | 1998-12-02 | Test du champ visuel par telemedecine |
Country Status (2)
Country | Link |
---|---|
CA (1) | CA2312924A1 (fr) |
WO (1) | WO1999027842A1 (fr) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2361374A (en) * | 2000-04-14 | 2001-10-17 | Anil Kumar Gupta | Ophthalmic dispensing via the internet |
WO2001087149A1 (fr) * | 2000-05-15 | 2001-11-22 | Boston Medical Technologies, Inc. | Systeme de telemesure d'essai medical |
WO2002000105A1 (fr) * | 2000-06-28 | 2002-01-03 | Aivision Pty Ltd | Systeme de test de la vue |
WO2001071636A3 (fr) * | 2000-03-23 | 2002-03-14 | Mitsubishi Chem Corp | Systeme et procede d'etablissement de profils de sante personnalises |
EP1216444A2 (fr) * | 1999-09-28 | 2002-06-26 | Sound ID | Procedes d'evaluation audiologique sur l'internet |
WO2002061526A3 (fr) * | 2000-12-15 | 2004-02-26 | Cybercare Technologies Inc | Systeme et procede de groupe de support video correcteur |
AU2001267152B2 (en) * | 2000-06-28 | 2006-02-02 | Aivision Pty Ltd | Vision testing system |
US10398304B2 (en) | 2013-03-12 | 2019-09-03 | Visibly, Inc. | Computerized testing and determination of a visual field of a patient |
WO2019169322A1 (fr) * | 2018-03-02 | 2019-09-06 | Ohio State Innovation Foundation | Systèmes et procédés de mesure de cartes de la fonction visuelle |
US10779733B2 (en) | 2015-10-16 | 2020-09-22 | At&T Intellectual Property I, L.P. | Telemedicine application of video analysis and motion augmentation |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5317405A (en) * | 1991-03-08 | 1994-05-31 | Nippon Telegraph And Telephone Corporation | Display and image capture apparatus which enables eye contact |
US5441047A (en) * | 1992-03-25 | 1995-08-15 | David; Daniel | Ambulatory patient health monitoring techniques utilizing interactive visual communication |
US5517021A (en) * | 1993-01-19 | 1996-05-14 | The Research Foundation State University Of New York | Apparatus and method for eye tracking interface |
-
1998
- 1998-12-02 CA CA002312924A patent/CA2312924A1/fr not_active Abandoned
- 1998-12-02 WO PCT/US1998/025485 patent/WO1999027842A1/fr active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5317405A (en) * | 1991-03-08 | 1994-05-31 | Nippon Telegraph And Telephone Corporation | Display and image capture apparatus which enables eye contact |
US5441047A (en) * | 1992-03-25 | 1995-08-15 | David; Daniel | Ambulatory patient health monitoring techniques utilizing interactive visual communication |
US5517021A (en) * | 1993-01-19 | 1996-05-14 | The Research Foundation State University Of New York | Apparatus and method for eye tracking interface |
Cited By (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1216444A4 (fr) * | 1999-09-28 | 2006-04-12 | Sound Id | Procedes d'evaluation audiologique sur l'internet |
EP1216444A2 (fr) * | 1999-09-28 | 2002-06-26 | Sound ID | Procedes d'evaluation audiologique sur l'internet |
WO2001071636A3 (fr) * | 2000-03-23 | 2002-03-14 | Mitsubishi Chem Corp | Systeme et procede d'etablissement de profils de sante personnalises |
GB2361374A (en) * | 2000-04-14 | 2001-10-17 | Anil Kumar Gupta | Ophthalmic dispensing via the internet |
WO2001087149A1 (fr) * | 2000-05-15 | 2001-11-22 | Boston Medical Technologies, Inc. | Systeme de telemesure d'essai medical |
US6650932B1 (en) | 2000-05-15 | 2003-11-18 | Boston Medical Technologies, Inc. | Medical testing telemetry system |
US7367675B2 (en) | 2000-06-28 | 2008-05-06 | Aivision Pty Ltd. | Vision testing system |
WO2002000105A1 (fr) * | 2000-06-28 | 2002-01-03 | Aivision Pty Ltd | Systeme de test de la vue |
AU2001267152B2 (en) * | 2000-06-28 | 2006-02-02 | Aivision Pty Ltd | Vision testing system |
WO2002061526A3 (fr) * | 2000-12-15 | 2004-02-26 | Cybercare Technologies Inc | Systeme et procede de groupe de support video correcteur |
US10398304B2 (en) | 2013-03-12 | 2019-09-03 | Visibly, Inc. | Computerized testing and determination of a visual field of a patient |
US10517476B2 (en) | 2013-03-12 | 2019-12-31 | Visibly, Inc. | Computerized testing and determination of a visual field of a patient |
US11666211B2 (en) | 2013-03-12 | 2023-06-06 | Visibly, Inc. | Computerized testing and determination of a visual field of a patient |
US10779733B2 (en) | 2015-10-16 | 2020-09-22 | At&T Intellectual Property I, L.P. | Telemedicine application of video analysis and motion augmentation |
WO2019169322A1 (fr) * | 2018-03-02 | 2019-09-06 | Ohio State Innovation Foundation | Systèmes et procédés de mesure de cartes de la fonction visuelle |
US10925481B2 (en) | 2018-03-02 | 2021-02-23 | Ohio State Innovation Foundation | Systems and methods for measuring visual function maps |
Also Published As
Publication number | Publication date |
---|---|
CA2312924A1 (fr) | 1999-06-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6033076A (en) | Visual field testing via telemedicine | |
US6027217A (en) | Automated visual function testing via telemedicine | |
US6386706B1 (en) | Visual function testing with virtual retinal display | |
US6592222B2 (en) | Flicker and frequency doubling in virtual reality | |
JP4786119B2 (ja) | 検眼システム、検眼装置、及びそのプログラム及び記録媒体、並びに、標準化方法 | |
JP5923445B2 (ja) | 緑内障の組み合わせ解析 | |
US5880812A (en) | Method and apparatus for evaluating and mapping visual field | |
US7938538B2 (en) | Methods and devices for rapid measurement of visual sensitivity | |
EP1219243A1 (fr) | Examen de la fonction cérébrale non invasife | |
US20050165327A1 (en) | Apparatus and method for detecting the severity of brain function impairment | |
CN110600103B (zh) | 一种提升视力的可穿戴智能服务系统 | |
JP2024512045A (ja) | メンタルヘルスを診断および監視するための視覚システム | |
JP2002253509A (ja) | 脳機能検査方法とその装置、脳機能検査システム、脳機能検査サービス方法及びそのプログラムと装置 | |
CN114246589A (zh) | 记忆认知能力测评方法及系统 | |
WO1999027842A1 (fr) | Test du champ visuel par telemedecine | |
CN114983434A (zh) | 一种基于多模态脑功能信号识别的系统及方法 | |
CN118415588A (zh) | 基于虚拟现实和眼动追踪技术的帕金森病诊断系统和设备 | |
EP3402388B1 (fr) | Système et procédé permettant de réaliser une périmétrie objective et un diagnostic de patients atteints de rétinite pigmentaire et d'autres maladies oculaires | |
KR20220077580A (ko) | 안구인식 데이터를 이용한 뇌신경계 질환 모니터링용 스마트 글래스 | |
CN113951828A (zh) | 一种基于视觉工作记忆任务的mci筛查方法及系统 | |
RU2690917C1 (ru) | Способ объективного измерения остроты зрения (варианты) | |
RU2357651C1 (ru) | Способ компьютерной диагностики открытоугольной глаукомы | |
CA2351876A1 (fr) | Doublage du scintillement et de la frequence en realite virtuelle | |
RU2207039C2 (ru) | Способ диагностики патологии сетчатки и зрительного нерва | |
Ananya et al. | Glaucoma Detection using HOG based features with Feed-forward Neural Networks and Extreme Learning Machine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): CA IL JP |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
ENP | Entry into the national phase |
Ref document number: 2312924 Country of ref document: CA Ref country code: CA Ref document number: 2312924 Kind code of ref document: A Format of ref document f/p: F |
|
122 | Ep: pct application non-entry in european phase |